UB-312 is under clinical development by Vaxxinity and currently in Phase I for Parkinson’s Disease. According to GlobalData, Phase I drugs for Parkinson’s Disease have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how UB-312’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
UB-312 is under development for the treatment of Parkinson's disease and multiple system atrophy (MSA) and for dementia with lewy bodies. The vaccine candidate is an endobody, it acts by targeting alpha-synuclein protein. It is developed based on synthetic peptide vaccine technology.
Vaxxinity is a biotechnology company that enables the innovation of synthetic peptide vaccines to prevent or treat infectious diseases. It offers an innovative platform that has the power to activate different arms of the immune system selectively and to neutralize targets with high specificity. Vaxxinity is headquartered in Merritt Island, Florida, the US.
For a complete picture of UB-312’s drug-specific PTSR and LoA scores, buy the report here.